183 related articles for article (PubMed ID: 33864599)
21. Atypical Presentation of Chorioretinal Folds-Related Maculopathy.
Corvi F; Capuano V; Benatti L; Bandello F; Souied E; Querques G
Optom Vis Sci; 2016 Oct; 93(10):1304-14. PubMed ID: 27560847
[TBL] [Abstract][Full Text] [Related]
22. Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a Noninterventional Trial.
Ziemssen F; Hammer T; Grueb M; Mueller B; Berk H; Gamulescu MA; Voegeler J; Wachtlin J; Ocean Study Group
J Ophthalmol; 2020; 2020():8652370. PubMed ID: 33083052
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections.
Singh SR; Chattannavar G; Ayachit A; Pimentel MC; Alfaro A; Tiwari S; Heranjal A; Subramanyam A; Braimah IZ; Dhami A; Sachdev P; Mansour A; Chhablani J
Semin Ophthalmol; 2020 Jan; 35(1):2-6. PubMed ID: 31690175
[No Abstract] [Full Text] [Related]
24. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
[TBL] [Abstract][Full Text] [Related]
25. The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab.
Storey PP; Tauqeer Z; Yonekawa Y; Todorich B; Wolfe JD; Shah SP; Shah AR; Koto T; Abbey AM; Morizane Y; Sharma P; Wood EH; Morizane-Hosokawa M; Pendri P; Pancholy M; Harkey S; Jeng-Miller KW; Obeid A; Borkar DS; Chen E; Williams P; Okada AA; Inoue M; Shiraga F; Hirakata A; Shah CP; Prenner J; Garg S;
Am J Ophthalmol; 2019 Mar; 199():200-208. PubMed ID: 30552891
[TBL] [Abstract][Full Text] [Related]
26. Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario.
Jain P; Sheth J; Anantharaman G; Gopalakrishnan M
Indian J Ophthalmol; 2017 Jul; 65(7):596-602. PubMed ID: 28724817
[TBL] [Abstract][Full Text] [Related]
27. Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Medication Use.
Thulliez M; Angoulvant D; Pisella PJ; Bejan-Angoulvant T
JAMA Ophthalmol; 2018 May; 136(5):557-566. PubMed ID: 29566105
[TBL] [Abstract][Full Text] [Related]
28. A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion.
Sharma S; ; Khan M; Chaturvedi A
Ophthalmol Ther; 2020 Sep; 9(3):625-639. PubMed ID: 32617913
[TBL] [Abstract][Full Text] [Related]
29. Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration.
Eng VA; Rayess N; Nguyen HV; Leng T
PLoS One; 2020; 15(5):e0232353. PubMed ID: 32369500
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
[TBL] [Abstract][Full Text] [Related]
31. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections.
Ladas ID; Karagiannis DA; Rouvas AA; Kotsolis AI; Liotsou A; Vergados I
Retina; 2009 Mar; 29(3):313-8. PubMed ID: 19287287
[TBL] [Abstract][Full Text] [Related]
32. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
33. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
[TBL] [Abstract][Full Text] [Related]
34. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.
Fung AE; Rosenfeld PJ; Reichel E
Br J Ophthalmol; 2006 Nov; 90(11):1344-9. PubMed ID: 16854824
[TBL] [Abstract][Full Text] [Related]
35. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
36. Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection.
Patel SN; Storey PP; Pancholy M; Obeid A; Wibbelsman TD; Levin H; Hsu J; Garg SJ; Dunn JP; Vander JF
Am J Ophthalmol; 2019 Nov; 207():224-231. PubMed ID: 31201794
[TBL] [Abstract][Full Text] [Related]
37. Experience of intravitreal injections in a tertiary Hospital in Oman.
Al-Hinai AS
Oman J Ophthalmol; 2015; 8(3):166-70. PubMed ID: 26903722
[TBL] [Abstract][Full Text] [Related]
38. A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration.
Jaffe GJ; Eliott D; Wells JA; Prenner JL; Papp A; Patel S
Ophthalmology; 2016 Jan; 123(1):78-85. PubMed ID: 26499921
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal bevacizumab: safety of multiple doses from a single vial for consecutive patients.
Ng DS; Kwok AK; Chan CW; Li WW
Hong Kong Med J; 2012 Dec; 18(6):488-95. PubMed ID: 23223649
[TBL] [Abstract][Full Text] [Related]
40. Incidence of post-intravitreal anti-VEGF endophthalmitis at Thammasat University Hospital.
Kanchanaranya N; Rojdamrongratana D; Piyasoonthorn P
J Med Assoc Thai; 2015 May; 98(5):489-94. PubMed ID: 26058278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
